Aditum Bio
Matthew Fitzpatrick's work experience begins in 2002 when they joined Cato Research as a Regulatory Affairs Associate II. Matthew worked there until 2009.
Matthew then worked at GSK as a Regulatory Submission Specialist for four years, from 2009 to 2013.
Afterward, they joined Pearl Therapeutics, where they served as a Manager, Regulatory Submissions from 2013 to 2017. Matthew then transitioned to the role of Regulatory Affairs Operations until 2018.
In 2021, they joined Latham BioPharm Group as a Consultant, Regulatory Operations until 2022.
Currently, they work at Aditum Bio as a Regulatory Project Manager from 2022 onwards.
Matthew Fitzpatrick attended Springfield College from 2001 to 2002, where they pursued a Bachelor of Science degree in Human Services, General.
This person is not in any offices
Aditum Bio
Aditum Bio is an investment fund that specializes in acquiring and developing pharmaceutical assets. It gives patients access to medicines that may not otherwise be developed. Aditum Bio was founded on 2019 and is headquartered in San Francisco, California.